Search | Clinical Trials Finder

Conditions: Peripheral Artery Disease (PAD); Intermittent Claudication
Interventions: LLG783, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Jacksonville, Florida • Columbus, Ohio

Conditions: Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Interventions: Transcu O2®; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Wounds, Diabetes, Venous Stasis Ulcers
Interventions: FGF-1; Drug
Lead sponsor: Venturis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warren, Pennsylvania

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions: Ad2/HIF-1α/VP16, Saline (Placebo Control); Biological · Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 35
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more

Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions: Bone marrow concentration device, Placebo procedure (sham); Device · Procedure
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 21 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 25
States / cities: Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more

Conditions: Peripheral Arterial Disease, Peripheral Artery Disease
Interventions: MitoQ; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Compartment Syndrome of Leg, Extracorporeal Membrane Oxygenation Complication, Limb Ischemia, Limb Ischemia, Critical
Interventions: MY01 + Standard of Care, 14-Gauge Slit Catheter + Standard of Care, Standard of Care; Device · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions: ABI/WIFI scoring; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetic Foot Ulcer, Peripheral Arterial Disease, Wound; Foot
Interventions: VibratoSleeve Therapeutic Ultrasound Device; Device
Lead sponsor: Vibrato Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Peripheral Arterial Disease, Diabetic Foot
Interventions: PDA-002, Placebo; Biological · Other
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more

Conditions: Critical Limb Ischemia
Interventions: VM202 2 mg, VM202 4 mg, VM202 8 mg, VM202 16 mg; Biological
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 20 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
Interventions: Usual care; Other
Lead sponsor: U.S. Wound Registry; Other
Eligibility: Not listed
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2030
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 99 Years
Enrollment: 7,829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Arterial Disease, Peripheral Artery Disease, Peripheral Vascular Diseases, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Foot Infection, Diabetic Peripheral Neuropathy
Interventions: Telemedicine specialty consultation; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
Interventions: Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care); Device
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years to 79 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Peripheral Vascular Disease
Interventions: Ecraprost in lipid emulsion; Drug
Lead sponsor: Tanabe Pharma Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Glendale, California + 12 more

Conditions: PERIPHERAL VASCULAR DISEASE
Interventions: Conventional angioplasty balloon, cryoplasty balloon; Procedure
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Davenport, Iowa • Oklahoma City, Oklahoma • Dallas, Texas

Conditions: Critical Limb Ischemia
Interventions: Liposuction, Stem Cell Injection; Procedure · Other
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetic Foot, Peripheral Arterial Disease
Interventions: PDA-002, Placebo; Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral Arterial Disease
Interventions: Lower leg heating, Lower leg transcutaneous electrical nerve stimulation (TENS); Behavioral
Lead sponsor: Salisbury University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salisbury, Maryland

Conditions: Diabetic Foot Ulcer
Interventions: Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroe, North Carolina

Conditions: Wounds and Injuries
Interventions: Allevyn Life, Foam dressing with an integrated adhesive border; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Tustin, California • Wichita, Kansas • McAllen, Texas

Conditions: Peripheral Arterial Disease
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 40 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Search by objective public record fields.

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

The Myelin Disorders Biorepository Project

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients

Implementation of ABI and WIfI in Rural Health Clinics

A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

Safety Study of Gene Therapy in Treating Critical Leg Ischemia

A Real-World Registry of Chronic Wounds and Ulcers

Evaluation of Patients With Heart Disease Not Eligible for Research Protocols

Implementation of Telemedicine for Patient With Lower Extremity Wounds

Safety and Efficacy of the Noxsano Wound Care Bandage

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Effect of Lower Leg Heating and Transcutaneous Electrical Nerve Stimulation on Exercise Capacity in Patients With PAD

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

Managing Wounds With Allevyn Life in a Home Health Care Environment

Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities